NO-1886

Lipoprotein lipase (LPL) mediates the hydrolysis of triglycerides in circulating very low density lipoproteins and chylomicrons. NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle. This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats. NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.Formal Name: [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-phosphonic acid diethyl ester. CAS Number: 133208-93-2. Synonyms: Ibrolipim, Lipoprotein Lipase Activator, LPL Activator, OPF 009. Molecular Formula: C19H20BrN2O4P. Formula Weight: 451.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 25 mg/ml, DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml, DMSO: 25 mg/ml, Ethanol: 2 mg/ml. lambdamax: 260 nm. SMILES: BrC1=CC(C#N)=C(NC(C2=CC=C(CP(OCC)(OCC)=O)C=C2)=O)C=C1. InChi Code: InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23). InChi Key: KPRTURMJVWXURQ-UHFFFAOYSA-N.